Early trajectory of inflammatory cytokines following tarlatamab administration in three advanced SCLC patients
Abstract Tarlatamab, a bispecific T-cell engager (BiTE), effectively activates the immune system but often causes cytokine release syndrome (CRS). To understand the early in vivo cytokine dynamics of post-BiTE therapy, we analyzed serum from three SCLC patients before and after tarlatamab administra...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Springer
2025-11-01
|
| Rangatū: | Cancer Immunology, Immunotherapy |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1007/s00262-025-04243-5 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|